Tesamorelin 10mg
Tesamorelin is a synthetic 44-amino-acid growth hormone-releasing factor (GHRF/GHRH) analog designed to stimulate the human growth hormone-releasing hormone receptor (GHRHR) and promote endogenous pulsatile growth hormone secretion. Its modified structure includes a hexenoyl moiety that enhances peptide stability.
Compound information
What is the Peptidef?
A synthetic copy of the full human GHRH hormone, all 44 amino acids, with one added chemical group at its front end. That modification shields it from the enzyme that quickly breaks down natural GHRH, letting it act on the pituitary far longer in research models.
Structure
Stability information
Product overview
A stabilized full-length GHRH analog supplied for laboratory evaluation at a ≥99% HPLC analytical standard.
Technical overview
Tesamorelin carries the complete 44-amino-acid sequence of human growth-hormone-releasing hormone, altered by a single addition: a trans-3-hexenoic acid group anchored to the N-terminal tyrosine. That fatty-acid extension blocks DPP-IV from cleaving the peptide at its usual site, the weakness that limits natural GHRH.
It is produced by solid-phase synthesis and preparative purification, then released against a lot-matched Certificate of Analysis carrying HPLC purity and LC-MS identity.
Research applications
Tesamorelin is studied as a stable probe for GHRH receptor pharmacology. Common laboratory work includes GHRHR binding and signaling assays on pituitary somatotroph cells, studies of pulsatile growth-hormone release, DPP-IV resistance and peptide-stability research, and metabolic models examining growth-hormone influence on lipid handling and visceral fat.
Kylo Peptides supplies this compound as a reference material for scientific inquiry. All applications must be conducted by qualified professionals in controlled laboratory environments. It has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease.
Frequently Researched Together
Frequently Asked Questions
Stability. Native GHRH is rapidly cleaved by the enzyme DPP-IV, which cuts it near the N-terminus. Tesamorelin carries the same 44-residue sequence but adds a trans-3-hexenoic acid group at the N-terminus that blocks that cut, so it stays active far longer in research settings.
Both are GHRH analogs, but they differ in length and stability. Tesamorelin is the full 44-amino-acid hormone with a stabilizing modification, while sermorelin is a shortened 29-amino-acid version without it. That makes tesamorelin more resistant to enzymatic breakdown in comparative research.
Analysis places every lot at ≥99% by HPLC, with mass spectrometry confirming its identity. Each batch passes independent third-party testing before it leaves, and you can retrieve the certificate for your lot using the number printed on the vial.
Cold and dry throughout. Store the lyophilized powder at −20 °C, sealed and shielded from light, and at −80 °C for longer storage. Once reconstituted, keep the solution at 2 to 8 °C, work through it within a validated window, and avoid cycling it between frozen and thawed.
The molecule is the active ingredient in an FDA-approved prescription medicine, developed by Theratechnologies and approved in 2010 for a specific medical indication. What Kylo supplies is research-grade material for laboratory use only, which is not the finished drug product and is not authorized for any human use.
No. Kylo Tesamorelin is a reagent characterized for in vitro laboratory research only. It is not formulated or labeled for humans or animals, is not a substitute for the approved drug product, and is supplied strictly to qualified researchers.
Backed By A Lot-Matched COA
Every tesamorelin order is tied to a certificate of analysis matched to the exact lot in your vial.
Shop catalog →
